Data Descriptor: Proteomic profiling across breast cancer cell lines and models

We performed quantitative proteomics on 61 human-derived breast cancer cell lines to a depth of ~13,000 proteins. The resulting high-throughput datasets were assessed for quality and reproducibility. We used the datasets to identify and characterize the subtypes of breast cancer and showed that they conform to known transcriptional subtypes, revealing that molecular subtypes are preserved even in under-sampled protein feature sets. All datasets are freely available as public resources on the LINCS portal. We anticipate that these datasets, either in isolation or in combination with complimentary measurements such as genomics, transcriptomics and phosphoproteomics, can be mined for the purpose of predicting drug response, informing cell line specific context in models of signalling pathways, and identifying markers of sensitivity or resistance to therapeutics.

[1]  C. Baumann,et al.  Loss of CBX2 induces genome instability and senescence-associated chromosomal rearrangements , 2020, The Journal of cell biology.

[2]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[3]  Cassandra Willyard New human gene tally reignites debate , 2018, Nature.

[4]  Ravi Iyengar,et al.  The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. , 2017, Cell systems.

[5]  Heiner Koch,et al.  Pharmacoproteomic characterisation of human colon and rectal cancer , 2017, Molecular systems biology.

[6]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[7]  Peter K. Sorger,et al.  Conservation of protein abundance patterns reveals the regulatory architecture of the EGFR-MAPK pathway , 2016, Science Signaling.

[8]  Joshua A. Bittker,et al.  Correlating chemical sensitivity and basal gene expression reveals mechanism of action , 2015, Nature chemical biology.

[9]  B. Leyland-Jones,et al.  Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs , 2015, Meta gene.

[10]  K. Kuhn,et al.  Low-pH Solid-Phase Amino Labeling of Complex Peptide Digests with TMTs Improves Peptide Identification Rates for Multiplexed Global Phosphopeptide Analysis. , 2015, Journal of proteome research.

[11]  Su-In Lee,et al.  The Proteomic Landscape of Triple-Negative Breast Cancer. , 2015, Cell reports.

[12]  Jeffrey R. Whiteaker,et al.  Proteogenomic characterization of human colon and rectal cancer , 2014, Nature.

[13]  Edward L. Huttlin,et al.  MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes , 2014, Analytical chemistry.

[14]  Adam A. Margolin,et al.  Assessing the clinical utility of cancer genomic and proteomic data across tumor types , 2014, Nature Biotechnology.

[15]  E. Winer,et al.  Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network , 2012, Cancer.

[16]  E. Citterio,et al.  The emerging role of Polycomb repressors in the response to DNA damage , 2012, Journal of Cell Science.

[17]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[18]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[19]  M. Selbach,et al.  Global quantification of mammalian gene expression control , 2011, Nature.

[20]  S. Gygi,et al.  ms3 eliminates ratio distortion in isobaric multiplexed quantitative , 2011 .

[21]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[23]  M. Mann,et al.  Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips , 2007, Nature Protocols.

[24]  James Inglese,et al.  Authentication of Human Cell Lines by STR DNA Profiling Analysis -- Assay Guidance Manual , 2013 .

[25]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[27]  S. Gygi,et al.  Correlation between Protein and mRNA Abundance in Yeast , 1999, Molecular and Cellular Biology.

[28]  J. Yates,et al.  An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.

[29]  M. Ewen,et al.  Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. , 1993, Genes & development.

[30]  D. Wessel,et al.  A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. , 1984, Analytical biochemistry.